RESUMEN
Background: Past studies in French Polynesia have identified suicide as a significant concern, with a measured annual incidence of 79.4 attempts per 100,000 population during 2008-2010. In response to the COVID-19 pandemic, a monitoring system was established to track and investigate suicide attempts (SA). Methods: A prospective study was conducted between April 2020 and March 2023, including all patients referred to the French Polynesia Hospital Center for SA. Demographic factors as well as clinical parameters were analyzed. Findings: During the study period, 895 SAs were registered and confirmed, with a crude annual rate of 106.7 events and the adjusted rate at 113.2 per 100,000 population. Substantial majority of SA happened in the island of Tahiti. Half of the subjects did not have psychiatric diagnosis. There was a significant increase in SA from year 1 to year 3, with young people (female more than male) particularly at risk, especially in Tahiti. The normalized incidence among females younger than 20-year-old was as high as 310.4 per 100,000 population. Interpretation: Our data revealed an overall 34.4% increase in SA in French Polynesia, with a striking 54.9% increase during the third year of pandemic. The last year's record high incidence, is confirmed by increased activity on suicide hotlines, notably in Tahiti. A correlation between COVID exposure and suicidal behaviors, both at the individual and social level, is suspected with young female in Tahiti being the most vulnerable. These findings highlight the need for reinforced prevention and an efficient suicide monitoring system even after the public health emergency was declared over. Funding: The study is investigator-initiated without funding.
RESUMEN
OBJECTIVE: To analyse the epidemiological data on suicide in French Polynesia (FP). METHODS: Data on suicides were collected from the Public Health Direction, Judicial Police Investigations Court of Justice records, the Centre d'Opérations et de Renseignements de la Gendarmerie, patient records for those hospitalized in psychiatry and from psychological autopsies. RESULTS: The dataset consisted of 316 suicide cases in FP over 25 years (1992-2016). In FP, suicide was more frequent in men (sex ratio 3.2:1), young people (mean age, 34.4 years) and individuals with previously diagnosed psychiatric disorders (100 of 316; 31.6%) The most common method of suicide was hanging (276 of 316; 87.3%). A history of previous suicide attempts was found in 25 of 56 (44.6%) of suicide cases, when documented. The most common potential triggering factors for suicide were emotional problems. The suicide rates have remained stable during 1992-2016 (mean 10.6/100 000 inhabitants per year), with periods of economic crises increasing suicide rates. CONCLUSIONS: These results provide valuable information to enable the effective targeting of suicide prevention strategies toward those at high risk. Economic crises had larger impacts in the French overseas territories than mainland France. Given the unprecedented economic impact of the Covid-19 pandemic in FP, there is an urgent need to implement suicide epidemiological surveillance and prevention programmes.
Asunto(s)
COVID-19 , Pandemias , Adolescente , Adulto , Humanos , Masculino , Estudios Retrospectivos , SARS-CoV-2 , Intento de SuicidioRESUMEN
PET imaging studies using 5-HT1A receptor radiotracers show a decreased density of this receptor in hippocampi of patients with Alzheimer's disease (AD) at advanced stages. However, current 5-HT1A receptor radiopharmaceuticals used in neuroimaging are antagonists, thought to bind to 5-HT1A receptors in different functional states (i.e., both the one which displays high affinity for agonists and is thought to mediate receptor activation, as well as the state which has low affinity for agonists). Comparing the PET imaging obtained using an agonist radiotracer, which binds selectively to functional receptors, with the PET imaging obtained using an antagonist radiotracer would therefore provide original information on 5-HT1A receptor impairment during AD. Quantitative autoradiography using [(18)F]F13640 and [(18)F]MPPF, a 5-HT1A agonist and antagonist, respectively, was measured in hippocampi of patients with AD (n = 25, at different Braak stages) and control subjects (n = 9). The neuronal density was measured in the same tissues by NeuN immunohistochemistry. The specific binding of both radiotracers was determined by addition of WAY-100635, a selective 5-HT1A receptor antagonist. The autoradiography distribution of both 5-HT1A PET radiotracers varied across hippocampus regions. The highest binding density was in the pyramidal layer of CA1. Incubation with Gpp(NH)p, a non-hydrolysable analogue of GTP, reduced significantly [(18)F]F13640 binding in hippocampal regions, confirming its preferential interaction with G-coupled receptors, and slightly increased [(18)F]MPPF binding. In the CA1 subfield, [(18)F]F13640 binding was significantly decreased at Braak stages I/II (-19%), Braak stages III/IV (-23%), and Braak stages V/VI (-36%) versus control. In contrast, [(18)F]MPPF binding was statistically reduced only at the most advanced Braak stages V/VI compared to control (-33%). Since [(18)F]F13640 and [(18)F]MPPF can be used in vivo in humans, this neuropharmacological paradigm supports testing the concept of functional imaging using agonist radiopharmaceuticals in future clinical studies.
Asunto(s)
Enfermedad de Alzheimer/metabolismo , Tomografía de Emisión de Positrones , Radiofármacos/metabolismo , Receptor de Serotonina 5-HT1A/metabolismo , Agonistas del Receptor de Serotonina 5-HT1/metabolismo , Antagonistas del Receptor de Serotonina 5-HT1/metabolismo , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/patología , Autopsia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Piperidinas/metabolismo , Unión Proteica/fisiología , Piridinas/metabolismoRESUMEN
OBJECTIVE: Since the description by Yaskin in 1931, it has been observed that pancreatic cancer and depression are two clinical entities that share a high affinity. This observation relies on the higher incidence of depressive syndromes associated with pancreatic cancer than in any other type of digestive tumor, and on the possible occurrence of depressive symptoms several months before the diagnosis of cancer. We present here a series of cases whose screening returned positive for depression-related diagnoses in the months prior to revelation of the cancer. METHOD: We employed a structured psychiatric interview based on DSM-IV criteria (SCID-I). The diagnoses considered were major depressive episode, minor depressive episode, and subsyndromal depression. All subjects were free of psychiatric history. RESULTS: Some 15 patients were initially included: 10 presented compatible criteria for a past depressive episode, 2 presented a major depressive episode, 4 met the diagnosis of minor depression, and 4 evidenced subsyndromal depression over the one-year period prior to cancer diagnosis. SIGNIFICANCE OF RESULTS: This series of cases is consistent with previous work on the subject that suggested an increased vulnerability to depressive events in the premorbid phase of pancreatic cancer. If the possibility of depressive syndromes constituting the early stages of neoplastic disease is a common idea, it is still impossible to determine the natural history of these two disorders and therefore their causal linkage.